Biopharmaceutical Processing Equipment and Consumables Market Size & Forecast

The Biopharmaceutical Processing Equipment and Consumables Market is expected to grow at a CAGR of 9.5% from 2024 to 2031 to reach $83.39 billion by 2031. The biopharmaceutical processing equipment and consumables market is driven by global initiatives supporting the adoption of biopharmaceuticals, capacity expansions of biopharmaceutical plants, and the growing adoption of single-use bioprocessing equipment and consumables. Further, the shift towards bioprocessing 4.0, emerging economies, and the rising adoption of personalized medicines offer lucrative opportunities for the players operating in the market.

Biopharmaceutical Processing Equipment and Consumables Market Growth Drivers

Growing Adoption of Single-use Bioprocessing Equipment for Commercial Production

So far, the biopharmaceutical processing industry has been dominated by stainless-steel/reusable equipment. Most biopharmaceutical manufacturing plants have fixed stainless-steel bioreactors, mixers, and bioprocessing vessels. However, in the last few years, the trend has been shifting towards the adoption of single-use/disposable equipment. This is attributed to various advantages this equipment has over conventional stainless-steel equipment, such as reduced manufacturing costs (by eliminating cleaning and cleaning validation steps).

Besides reducing the time and labor required, single-use technologies also help reduce capital costs and energy consumption, improving efficiency. Although single-use systems generate waste from incinerating and discarding plastic materials, they still leave a smaller carbon footprint than permanent steel systems. The carbon dioxide released after generating steam for water for injection (WFI) cleaning and the steam-in-place sterilization of stainless-steel vessels, piping, and other hardware are far more than the carbon dioxide produced from the manufacture and disposal of plastic single-use systems. Thus, the usage of WFI, steam, and cleaning agents is reduced significantly by incorporating single-use platforms.

Click here to: Get Free Sample Pages of this Report

Capacity Expansions of Biopharmaceutical Plants

Biosimilars and biologics are gaining significant importance in oncology, autoimmune diseases, and rare diseases. To meet the growing demand for biopharmaceuticals, several manufacturers are expanding their manufacturing facilities. These capacity expansions from biopharmaceutical manufacturers and CDMOs will generate additional demand for biopharmaceutical manufacturing equipment and consumables and thereby propel market growth. Some of the instances for biopharmaceutical plants capacity include:

• In January 2024, AbbVie Inc. (U.S.) announced the expansion of its biologics manufacturing facility in Singapore with an investment of USD 223 million.
• In November 2023, Eli Lilly and Company (U.S.) announced USD 2.5 billion for the opening of a new facility for the capacity of the company’s parenteral (injectable) product.

Biopharmaceutical Processing Equipment and Consumables Market Trends

Growing Focus on Continuous Bioprocessing

For a long time, batch/fed-batch mode has dominated the manufacturing of biopharmaceuticals. However, it has some limitations - it requires additional instruments for feedback control and has costly operation costs compared to continuous bioprocessing. In continuous bioprocessing, the process is performed at a single location without interruption, as there is a continuous flow of raw materials in and out of the bioreactor with the processing of the intermediate or final product - in contrast to batch culture - in which specific quantity of product is produced in a discrete volume during the same cycle of manufacture. The process is frequently segmented into many individual steps that are often performed at separate facilities. Moreover, continuous processing leads to the production of a quality end product with no variation and offers steady-state operation, reduced equipment size, streamlined process flow, and reduced capital costs.

Due to the growing demand for innovative and complex therapies and the growing competition in the biopharmaceuticals market, biopharmaceutical manufacturers are reconsidering manufacturing methods (shifting from batch to continuous manufacturing). Although batch manufacturing is the most preferred method, continuous manufacturing is increasingly accepted in the pharmaceutical industry due to its commercial advantages.

Strong R&D Pipeline of Biopharmaceuticals

At present, antibody-based biopharmaceuticals are dominating the market. There is a large number of antibody-based biopharmaceuticals present in the clinical pipeline of various biopharmaceutical companies. As per the data released by an international non-profit antibody-related research and development organization, The Antibody Society, as of January 10, 2021, 21 investigational antibody therapeutics are under regulatory review in the U.S. and European Union. From January 1, 2021, to December 31, 2021, 13 antibody therapeutics were granted first approvals in either the U.S. or European Union. Moreover, in 2023, the Center for Drug Evaluation and Research (CDER) approved 55 novel drugs and biological products. Thus, with more biopharmaceuticals entering a commercial stage, the demand for bioprocessing equipment and consumables used in their production is expected to grow.

Biopharmaceutical Processing Equipment and Consumables Market Opportunities

Shift Towards Bioprocessing 4.0

The rapid development in emerging economies, progressing research in biologics, and the growing penetration of biopharmaceuticals have created tremendous opportunities for biopharmaceutical manufacturers, boosting the demand for biopharmaceutical processing equipment and consumables. The manufacturing of biologics has grown over the last few years. The industry is shifting towards Bioprocessing 4.0, a term derived from Industry 4.0, which is a national strategic initiative launched by the German government in 2010. Biomanufacturing 4.0 is still in its infancy. Bioprocessing 4.0 is defined as an end-to-end connected bioprocess, where all equipment and systems in the process are connected digitally, forming the Industrial Internet of Things (IoT) to run, control, and enhance the process through feedback loops and machine learning or artificial intelligence (AI).

Biopharmaceutical Processing Equipment and Consumables Market Analysis: Key Findings

By Product Type: In 2024, the Filtration Segment is Expected to Dominate the Biopharmaceutical Processing Equipment and Consumables Market

Based on product type, the global biopharmaceutical processing equipment and consumables market is segmented into filtration systems, chromatography equipment and consumables, bioreactors, cell culture products, mixers/mixing systems, bioprocessing containers, sterilizers, centrifuges, incubators, shakers, biosafety cabinets, and other consumables and accessories. In 2024, the filtration systems segment is estimated to account for the largest share of 22.3% of the global biopharmaceutical processing equipment and consumables market. The large share of this segment is attributed to the recurring use of filtration at every step in bioprocessing and technological advancements in filtration technologies.

The process of filtration is the basic requisite across all stages of bioproduction. Filtration is commonly used in biopharmaceutical processing for separating components. It is used in various downstream operations, such as clarification, filtration of intermediates, critical final filling applications, or upstream processing for sterilizing-grade filtration of cell culture media.

However, the bioreactors segment is expected to grow at the highest CAGR of 12.9% during the forecast period of 2024 to 2031. The accelerated development of biopharmaceuticals for therapeutic indications like cancer, rare diseases, and infectious diseases; new product developments; and the growing deployment of single-use bioprocessing technologies are the factors driving the growth of the bioreactors segment.

Bioreactors, also called fermenters, are containers that provide an ideal environment for enzymes or whole cells to transform biochemicals into products. Bioreactors are used for many applications, including cell growth, enzyme production, biocatalysis, tissue engineering, algae production, protein synthesis, and anaerobic digestion. According to the Pharmaceutical Research and Manufacturers of America (PhRMA) (U.S.), currently, there are over 8,000 medicines in development, out of which 74% are potential first-in-class indicators for cancer, cardiovascular disorders, diabetes, Alzheimer’s disease, and rare diseases. As bioreactors are essential for the manufacturing of biopharmaceuticals, the growing development of biologics and biosimilars drives the segment growth during the forecast period.

By Application: In 2024, the Commercial Bioproduction Segment is Expected to Dominate the Biopharmaceutical Processing Equipment and Consumables Market

Based on application, the global biopharmaceutical processing equipment and consumables market is segmented into commercial bioproduction and research bioproduction. In 2024, The commercial bioproduction segment is estimated to account for the larger share of 77.5% of the global biopharmaceutical processing equipment and consumables market.

Growing initiatives supporting the adoption of biopharmaceuticals, rising biopharmaceutical manufacturing outsourcing, and accelerated developments in personalized therapies are likely to enhance the demand for bioprocessing equipment and consumables for the commercial bioproduction of monoclonal antibodies (mAbs), vaccines, gene therapies, and recombinant protein-based therapies.

A large number of pharmaceutical companies and contract manufacturing organizations (CMOs) involved in the manufacturing of biopharmaceuticals are witnessing high demand to produce biopharmaceuticals. In order to cater to the increasing demand, they are expanding their present manufacturing capacities, which would further increase the demand for biopharmaceutical equipment and consumables for commercial bioproduction during the forecast period. Besides this, the growing prevalence of various chronic and infectious diseases and regulatory reforms favoring the adoption of biosimilars are expected to drive the growth of the commercial bioproduction segment at the highest CAGR of 10.2% during the forecast period of 2024 to 2031.

By End User: In 2024, the Pharmaceutical and Biopharmaceutical Companies Segment is Expected to Account for the Largest Share of the Biopharmaceutical Processing Equipment and Consumables Market

Based on end user, the global biopharmaceutical processing equipment and consumables market is categorized into pharmaceutical & biopharmaceutical companies; contract development and manufacturing organizations (CDMOs); and academic & research institutes. In 2024, the pharmaceutical & biopharmaceutical companies segment is estimated to account for the largest share of the global biopharmaceutical processing equipment and consumables market.

Capacity expansion of biopharmaceutical manufacturers and the growing adoption of biopharmaceutical processing equipment for bioproduction is the key factor attributing to the largest market share. The development and manufacturing of biopharmaceuticals are gaining pace. Biopharmaceuticals account for nearly 25% of the pharmaceutical market. Thus, the growing manufacturing of biopharmaceuticals by biopharmaceutical companies contributes to the large segment share.

However, the contract development and manufacturing organizations (CDMO) segment is expected to grow the fastest CAGR during the forecast period of 2024 to 2031. The growth of the segment is attributed to the growing preference of pharmaceutical and biopharmaceutical companies to outsource the development and manufacturing to the CDMOs due to the cost, operational, and regulatory advantages offered by the CDMOs.

Geographical Analysis

In 2024, Europe is estimated to account for the largest share of 33.2% of the global biopharmaceutical processing equipment and consumables market. The large share of Europe in the biopharmaceutical processing equipment and consumables market is primarily attributed to the presence of leading biopharmaceutical manufacturers in the region, growing exports from Switzerland and Denmark, and the expansion of biopharmaceutical companies. Additionally, rising production capacities of the vaccine manufacturing plants, to meet the growing demand for COVID-19 vaccines has also contributed to the largest market.

However, Asia-Pacific is expected to grow at the fastest CAGR of 10.2% during the forecast period. The growth in this market is attributed to factors like growing outsourcing of biopharmaceutical manufacturing in countries like China, India, Singapore, and South Korea; rising public and private initiatives to boost the biotechnology research for the development of novel treatments for chronic diseases; and growing initiatives supporting the adoption of biopharmaceuticals. Further, growing awareness of personalized medicines and the development of biotechnology incubators are also accelerating the market growth.

Biopharmaceutical Processing Equipment and Consumables Market: Key Companies

The report includes a competitive landscape based on an extensive assessment of the key strategic developments that led market participants to adopt over the past three years (2021-2024). The key players profiled in the global biopharmaceutical processing equipment and consumables market report are 3M Company (U.S.), Thermo Fisher Scientific, Inc. (U.S.), Bio-Rad Laboratories, Inc. (U.S.), Danaher Corporation (U.S.), Agilent Technologies, Inc (U.S.), Repligen Corporation (U.S.), Sartorius AG (Germany), Merck KGaA (Germany), Eppendorf AG (Germany), and Solaris Biotechnology Srl (Italy).

Biopharmaceutical Processing Equipment and Consumables Industry Overview: Latest Developments from Key Industry Players

• In April 2023, Cytiva (U.S.) launched X-platform bioreactors to streamline the single-use upstream bioprocessing operations.
• In May 2024, Waters Corporation (U.S.) introduced the next-generation Alliance iS Bio HPLC System to increase the efficiency of quality control biopharma labs and reduce errors.
• In September 2023, Getinge AB (Sweden) launched AppliFlex ST GMP, a single-use bioreactor, to increase the efficiency of research and clinical production in cell and gene therapy and mRNA production.

Biopharmaceutical Processing Equipment and Consumables Market Research Summary

Key questions answered in the biopharmaceutical processing equipment and consumables market report: